Publication of Data Concerning CAVATAK in Breast Cancer
BRISBANE, Australia, 13 February 2008--Viralytics Limited is pleased to announce the publication of pre-clinical research data on the anticancer activity of its lead oncolytic virus candidate, CAVATAK™ (Coxsackievirus A21) on human breast cancers both in vitro and in vivo. The research was performed by staff at the University of Newcastle.
The peer reviewed publication titled, “Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21” is published in the international journal “Breast Cancer Research and Treatment” and is now available online. The abstract is available at the following link:
http://www.springerlink.com/content/r330657062775847/
The article describes the activity of intravenous injections of CAVATAK™ on the growth of human breast cancer cells in laboratory cultures and in mouse models. Single intravenous injections of CAVATAK™ produced significant regression of pre-established tumors in vivo in mice, as well as targeting and elimination of breast cancer metastases.
Such pre-clinical research data is a key component of the Company capacity to initiate human Phase I trials using CAVATAK™.
Other publications
Previous publications made by the Company and its researchers are available on the Company’s website www.viralytics.com
Bryan Dulhunty
Executive Chairman
About Viralytics Ltd: Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics’ principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics’ proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the community. CVA21 has been associated with upper respiratory infection ( “cold” like symptoms) and is self limiting, requiring no specific treatment for those infected to completely recover. In order to infect a cell, CVA21 must first attach to the outside of a cell, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF).
Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others.
Posted: February 2008
